International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Thrombosis and Haemostasis

Volumn 118, Issue 3, 2018, Pages 437-450

  Gosselin, Robert C ^a   Adcock, Dorothy M ^b   Bates, Shannon M ^c   Douxfils, Jonathan ^d   Favaloro, Emmanuel J ^e   Gouin Thibault, Isabelle ^f,k   Guillermo, Cecilia ^g   Kawai, Yohko ^h   Lindhoff Last, Edelgard ⁱ   Kitchen, Steve ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Colorado Coagulation ^*  (United States)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^d UNIVERSITY OF NAMUR   (Belgium)

^e WESTMEAD HOSPITAL   (Australia)

^f Faculte de Pharmacie   (France)

^g DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^h FUKUOKA SANNO HOSPITAL   (Japan)

ⁱ CCB Vascular Center CCB Coagulation Center   (Germany)

^j ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^k RENNES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

direct oral anticoagulants; laboratory guidance; laboratory measurement; recommendations

Indexed keywords

APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; FACTOR IIA; PROTHROMBIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; GOOD LABORATORY PRACTICE; HEMOSTASIS; HUMAN; INTERNATIONAL COOPERATION; INTERNATIONAL COUNCIL FOR STANDIZATION; MASS SPECTROMETRY; POINT OF CARE SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; VALIDATION PROCESS; CHROMATOGRAPHY; HEALTH CARE QUALITY; HEMATOLOGY; LABORATORY TECHNIQUE; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PROCEDURES; STANDARDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CHROMATOGRAPHY; CLINICAL LABORATORY TECHNIQUES; DABIGATRAN; HEMATOLOGY; HUMANS; INTERNATIONAL COOPERATION; MASS SPECTROMETRY; PARTIAL THROMBOPLASTIN TIME; POINT-OF-CARE TESTING; PROTHROMBIN; PROTHROMBIN TIME; PYRAZOLES; PYRIDINES; PYRIDONES; QUALITY ASSURANCE, HEALTH CARE; RIVAROXABAN; THIAZOLES;

EID: 85041900282     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1627480     Document Type: Article

References (138)

1. European Medicines Agency - Pradaxa - Procedure EMEA/H/C/829. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/000829/WC500041062.pdf. Accessed February 28, 2017
2. Dale B. J. Chan N. C. Eikelboom J. W. Laboratory measurement of the direct oral anticoagulants. Br J Haematol: 2016; 172 03 315 336
3. Douxfils J. Gosselin R. C. Laboratory assessment of direct oral anticoagulants (DOACs). Semin Thromb Hemost: 2017; 43 03 277 290
4. Pradaxa [package insert]. Boehringer Ingelheim Pharmaceuticals Inc, Ingelheim am Rhein, Germany. Revised November 2015. Accessed December 31, 2016
5. Blech S. Ebner T. Ludwig-Schwellinger E. Stangier J. Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos: 2008; 36 02 386 399
6. Wienen W. Stassen J. M. Priepke H. Ries U. J. Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost: 2007; 98 01 155 162
7. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet: 2008; 47 05 285 295
8. Stangier J. Rathgen K. Stähle H. Gansser D. Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol: 2007; 64 03 292 303
9. Samuelson B. T. Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev: 2017; 31 01 77 84
10. Reilly P. A. Lehr T. Haertter S., et al. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol: 2014; 63 04 321 328
11. Perzborn E. Strassburger J. Wilmen A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost: 2005; 3 03 514 521
12. Depasse F. Busson J. Mnich J. Le Flem L. Gerotziafas G. T. Samama M. M. Effect of BAY 59-7939-a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. J Thromb Haemost 2005;3(Suppl 1):Abstract P1104
13. Kubitza D. Perzborn E. Berkowitz S. D. The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol: 2013; 4 145
14. European Medicines Agency. Xarelto - Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed January 15, 2017
15. Mueck W. Stampfuss J. Kubitza D. Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet: 2014; 53 01 1 16
16. Food and Drug Administration. Xarelto-Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202439s001lbl.pdf. Accessed January 15, 2017
17. Zhang D. He K. Raghavan N., et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos: 2009; 37 08 1738 1748
18. Mani H. Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther: 2014; 8 789 798
19. European Medicines Agency. Eliquis - Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002148/WC500107728.pdf. Accessed January 15, 2017
20. Furugohri T. Isobe K. Honda Y., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost: 2008; 6 09 1542 1549
21. Ogata K. Mendell-Harary J. Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol: 2010; 50 07 743 753
22. Giugliano R. P. Ruff C. T. Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
23. Büller H. R. Décousus H. Grosso M. A., et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med: 2013; 369 15 1406 1415
24. Fuji T. Wang C. J. Fujita S. Kawai Y. Kimura T. Tachibana S. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty: 2014; 29 12 2439 2446
25. Fuji T. Wang C. J. Fujita S., et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res: 2014; 134 06 1198 1204
26. Weitz J. I. Connolly S. J. Patel I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost: 2010; 104 03 633 641
27. Ruff C. T. Giugliano R. P. Braunwald E., et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet: 2015; 385 (9984): 2288 2295
28. Verhamme P. Wells P. S. Segers A., et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost: 2016; 116 04 747 753
29. Fuji T. Fujita S. Kawai Y., et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res: 2014; 133 06 1016 1022
30. Gosselin R. C. Adcock D. M. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost: 2016; 14 05 886 893
31. Adams H. P. Jr. del Zoppo G. Alberts M. J. Bhatt D. L. Brass L. Furlan A. Grubb R. L. Higashida R. T. Jauch E. C. Kidwell C. Lyden P. D. Morgenstern L. B. Qureshi A. I. Rosenwasser R. H. Scott P. A. Wijdicks E. F.; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke: 2007; 38 05 1655 711. Epub 2007 Apr 12. Erratum in: Stroke. 2007 Jun;38(6)
32. Harenberg J. Krämer S. Du S., et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest: 2014; 44 08 743 752
33. McGrail R. Revsholm J. Nissen P. H. Grove E. L. Hvas A. M. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res: 2016; 148 107 110
34. Gous T. Couchman L. Patel J. P. Paradzai C. Arya R. Flanagan R. J. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit: 2014; 36 05 597 605
35. Lessire S. Douxfils J. Baudar J., et al. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb Res: 2015; 136 03 693 696
36. Gosselin R. C. Adcock D. Hawes E. M. Francart S. J. Grant R. P. Moll S. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost: 2015; 113 01 77 84
37. Harenberg J. Marx S. Diener H-C., et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol: 2012; 31 04 330 339
38. van Ryn J. Stangier J. Haertter S., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 06 1116 1127
39. Samama M. M. Contant G. Spiro T. E., et al. Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost: 2012; 18 02 150 158
40. Douxfils J. Mullier F. Loosen C. Chatelain C. Chatelain B. Dogné J-M. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res: 2012; 130 06 956 966
41. Douxfils J. Mullier F. Robert S. Chatelain C. Chatelain B. Dogné J-M. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost: 2012; 107 05 985 997
42. Halbmayer W-M. Weigel G. Quehenberger P., et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med: 2012; 50 09 1601 1605
43. Hillarp A. Baghaei F. Fagerberg Blixter I., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost: 2011; 9 01 133 139
44. Mani H. Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol: 2014; 36 03 261 268
45. Kitchen S. Gray E. Mackie I. Baglin T. Makris M.; BCSH Committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol: 2014; 166 06 830 841
46. Van Blerk M. Bailleul E. Chatelain B., et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost: 2015; 113 01 154 164
47. Testa S. Legnani C. Tripodi A., et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost: 2016; 14 11 2194 2201
48. Hawes E. M. Deal A. M. Funk-Adcock D., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost: 2013; 11 08 1493 1502
49. Gouin-Thibault I. Flaujac C. Delavenne X., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost: 2014; 111 02 240 248
50. Douxfils J. Chatelain C. Chatelain B. Dogné J-M. Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost: 2013; 110 02 283 294
51. Bonar R. Favaloro E. J. Mohammed S., et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology: 2016; 48 01 60 71
52. Cuker A. Siegal D. M. Crowther M. A. Garcia D. A. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol: 2014; 64 11 1128 1139
53. Douxfils J. Chatelain B. Chatelain C. Dogné J-M. Mullier F. Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost: 2016; 115 02 368 381
54. Zafar M. U. Vorchheimer D. A. Gaztanaga J., et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost: 2007; 98 04 883 888
55. Morishima Y. Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol: 2015; 143 02 241 247
56. Helin T. A. Pakkanen A. Lassila R. Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem: 2013; 59 05 807 814
57. Tripodi A. Chantarangkul V. Guinet C. Samama M. M. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost: 2011; 9 01 226 228
58. Jabet A. Stepanian A. Golmard J. L. Flaujac C. Joly B. S. Gouin-Thibault I. Siguret V. Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations? Chest: 2018; 153 01 288 290
59. Francart S. J. Hawes E. M. Deal A. M., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost: 2014; 111 06 1133 1140
60. Tsutsumi Y. Shimono J. Ohhigashi H. Ito S. Shiratori S. Teshima T.; Int J Lab. Analysis of the influence of dabigatran on coagulation factors and inhibitors. Int J Lab Hematol: 2015; 37 02 225 230
61. Gosselin R. C. Adcock D. M. Comment: analysis of the influence of dabigatran on coagulation factors and inhibitors. Int J Lab Hematol: 2016; 38 01 e4
62. Gosselin R. Grant R. P. Adcock D. M. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol: 2016; 38 05 505 513
63. Dager W. E. Gosselin R. C. Kitchen S. Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother: 2012; 46 12 1627 1636
64. Dias J. D. Norem K. Doorneweerd D. D. Thurer R. L. Popovsky M. A. Omert L. A. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med: 2015; 139 05 665 673
65. Herrmann R. Thom J. Wood A. Phillips M. Muhammad S. Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost: 2014; 111 05 989 995
66. Adelmann D. Wiegele M. Wohlgemuth R. K., et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res: 2014; 134 04 918 923
67. Chojnowski K. Górski T. Robak M. Treliński J. Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism. Adv Clin Exp Med: 2015; 24 06 995 1000
68. Körber M. K. Langer E. Köhr M. Wernecke K. D. Korte W. von Heymann C. In vitro and ex vivo measurement of prophylactic dabigatran concentrations with a new ecarin-based thromboelastometry test. Transfus Med Hemother: 2017; 44 02 100 105
69. Fontana P. Alberio L. Angelillo-Scherrer A., et al. Impact of rivaroxaban on point-of-care assays. Thromb Res: 2017; 153 65 70
70. Ebner M. Peter A. Spencer C., et al. Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants. Stroke: 2015; 46 10 2741 2747
71. Al-Aieshy F. Malmström R. E. Antovic J., et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol: 2016; 72 06 671 679
72. Mani H. Herth N. Kasper A., et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit: 2014; 36 05 624 631
73. Ebner M. Birschmann I. Peter A., et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care: 2017; 21 01 32
74. Hemachron Jr Whole Blood Microcoagulation system. Prothrombin time (PT) [package insert]. Edison, NJ International Technidyne Corporation Revision March: 2007
75. Du S. Weiss C. Christina G., et al. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med: 2015; 53 08 1237 1247
76. DOASENSE GmbH. Heidelberg, Germany. 2017 https://www.doasense.de/Press-Release-of-DOASENSE-GmbH.PDF
77. Vogeser M. Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory - goals for further developments. Clin Biochem: 2008; 41 09 649 662
78. Adaway J. E. Keevil B. G. Therapeutic drug monitoring and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci: 2012; 883-884: 33 49
79. Kubitza D. Becka M. Wensing G. Voith B. Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol: 2005; 61 12 873 880
80. Rohde G. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci: 2008; 872 (1-2): 43 50
81. Barrett Y. C. Wang J. Song Y., et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost: 2012; 107 05 916 924
82. Bathala M. S. Masumoto H. Oguma T. He L. Lowrie C. Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos: 2012; 40 12 2250 2255
83. Schmitz E. M. Boonen K. van den Heuvel D. J., et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost: 2014; 12 10 1636 1646
84. Douxfils J. Dogné J. M. Mullier F., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost: 2013; 110 03 543 549
85. Douxfils J. Tamigniau A. Chatelain B., et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost: 2013; 110 04 723 731
86. Antovic J. P. Skeppholm M. Eintrei J., et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol: 2013; 69 11 1875 1881
87. Skeppholm M. Hjemdahl P. Antovic J. P., et al. On the monitoring of dabigatran treatment in real life patients with atrial fibrillation. Thromb Res: 2014; 134 04 783 789
88. Skeppholm M. Al-Aieshy F. Berndtsson M., et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res: 2015; 136 01 148 153
89. Vogeser M. Seger C. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem: 2010; 56 08 1234 1244
90. Annesley T. Majzoub J. Hsing A. Wu A. Rockwood A. Mason D. Mass spectrometry in the clinical laboratory: how have we done, and where do we need to be? Clin Chem: 2009; 55 06 1236 1239
91. Clarke W. Rhea J. M. Molinaro R. Challenges in implementing clinical liquid chromatography-tandem mass spectrometry methods - the light at the end of the tunnel. J Mass Spectrom: 2013; 48 07 755 767
92. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb: 2003; 33 04 173 183
93. Pötzsch B. Hund S. Madlener K. Unkrig C. Müller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res: 1997; 86 05 373 383
94. Lindhoff-Last E. Piechottka G. P. Rabe F. Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res: 2000; 100 01 55 60
95. Gosselin R. Hawes E. Moll S. Adcock D. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol: 2014; 141 02 262 267
96. Lange U. Nowak G. Bucha E. Ecarin chromogenic assay - a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb: 2003; 33 04 184 191
97. Douxfils J. Lessire S. Dincq A. S., et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost: 2015; 113 04 862 869
98. Biophen DTI [package insert]. Neuville-sur-Oise, France: Hyphen Biomedical. Revision April 29, 2015
99. Helin T. A. Lemponen M. Hjemdahl P. Rönquist-Nii Y. Lassila R. Joutsi-Korhonen L. From laboratory to clinical practice: dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res: 2015; 136 01 154 160
100. Love J. E. Ferrell C. Chandler W. L. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost: 2007; 98 01 234 242
101. Avecilla S. T. Ferrell C. Chandler W. L. Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol: 2012; 137 04 572 574
102. Stangier J. Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis: 2012; 23 02 138 143
103. Hemoclot Thrombin Inhibitors [package insert]. Neuville-sur-Oise, France: Hyphen Biomedical. Revision March 17, 2015
104. HemosIL Direct Thrombin Inhibitors [package insert]. Bedford, MA: Instrumentation Laboratory. Revision March 2016
105. Douxfils J. Mani H. Minet V., et al. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. BioMed Res Int: 2015; 2015 345138
106. Douxfils J. Tamigniau A. Chatelain B. Goffinet C. Dogné J. M. Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J: 2014; 12 24
107. Becker R. C. Alexander J. H. Newby L. K., et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost: 2010; 104 05 976 983
108. Becker R. C. Yang H. Barrett Y., et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis: 2011; 32 02 183 187
109. Douxfils J. Chatelain B. Hjemdahl P., et al. Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res: 2015; 135 05 852 860
110. Gosselin R. C. Adcock Funk D. M. Taylor J. M., et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med: 2014; 138 12 1680 1684
111. Hillarp A. Gustafsson K. M. Faxälv L., et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost: 2014; 12 09 1545 1553
112. Mani H. Hesse C. Stratmann G. Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost: 2013; 109 01 127 136
113. Lindhoff-Last E. Samama M. M. Ortel T. L. Weitz J. I. Spiro T. E. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit: 2010; 32 06 673 679
114. Samama M. M. Amiral J. Guinet C. Perzborn E. Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost: 2010; 104 05 1078 1079
115. Samama M. M. Contant G. Spiro T. E., et al. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost: 2012; 107 02 379 387
116. Samama M. M. Guinet C. Le Flem L. Ninin E. Debue J. M. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis: 2013; 35 02 140 146
117. Samama M. M. Martinoli J. L. LeFlem L., et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost: 2010; 103 04 815 825
118. Samama M. M. Mendell J. Guinet C. Le Flem L. Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res: 2012; 129 04 e77 e82
119. Lessire S. Douxfils J. Pochet L., et al. Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging. Clin Appl Thromb Hemost: 2018; 24 01 129 138
120. Mani H. Rohde G. Stratmann G., et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost: 2012; 108 01 191 198
121. Gosselin R. C. Francart S. J. Hawes E. M. Moll S. Dager W. E. Adcock D. M. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother: 2015; 49 07 777 783
122. Yates S. G. Smith S. Tharpe W. Shen Y. M. Sarode R. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban? Transfus Apheresis Sci: 2016; 55 02 212 215
123. Adcock D. M. Gosselin R. Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res: 2015; 136 01 7 12
124. Sabor L. Raphaël M. Dogné J. M. Mullier F. Douxfils J. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res: 2017; 156 36 38
125. Harenberg J. Du S. Krämer S., et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost: 2013; 39 01 66 71
126. Harenberg J. Krämer S. Du S. Weiss C. Krämer R. Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J: 2013; 11 01 15
127. Harenberg J. Du S. Wehling M., et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med: 2016; 54 02 275 283
128. Harris L. F. Rainey P. Castro-López V. O'Donnell J. S. Killard A. J. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. Analyst (Lond): 2013; 138 17 4769 4776
129. Bluecher A. Meyer Dos Santos S. Ferreirós N., et al. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients. Thromb Haemost: 2017; 117 03 519 528
130. Specific PoC Testing of Coagulation in Patients Treated With NOAC 1 (SPOCT-NOAC 1) [Identifier: NCT02825394]. Available at: www.clinicaltrials.gov. Accessed January 15, 2017
131. FDA. Guidance for Industry Bioanalytical Method Validation. 2001, Revised 2013. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed January 15, 2017
132. Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH harmonised tripartite guideline. 2005. Available at: www.ich.org. Accessed January 15, 2017
133. Guidance for Industry Q2B Validation of Analytical Procedures: Methodology. 1996. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed January 15, 2017
134. US Department of Health and Human Services. Clinical laboratory improvement amendments of 1988: final rule. Fed Regist: 1992; 57 40 7001 7186. Codified at 42 CFR §1405-494
135. Thompson M. Ellison S. Wood R. Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC Technical Report). Pure Appl Chem: 2002; 74 835 855
136. Magnussen B. Örnemark U. (eds.). The fitness for purpose of analytical methods. A laboratory guide to method validation and related topics. 2nd edition. Eurachem, 2014. ISBN 978-9187461-59-0) (www.eurachem.org)
137. Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2 http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf
138. Bonar R. Favaloro E. J. Mohammed S. Pasalic L. Sioufi J. Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology: 2015; 47 04 355 364